021-51111890
购物车（）
sales@molnova.cn
3α-Aminocholestane
CAS No. 2206-20-4
3α-Aminocholestane ( —— )
产品货号. M33248 CAS No. 2206-20-4
3α-Aminocholestane 是含有选择性 SH2 结构域的肌醇-5'-磷酸酶 1 (SHIP1) 的抑制剂，其 IC50值约为 2.5 μM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥1424 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称3α-Aminocholestane
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述3α-Aminocholestane 是含有选择性 SH2 结构域的肌醇-5'-磷酸酶 1 (SHIP1) 的抑制剂，其 IC50值约为 2.5 μM。
-
产品描述3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC50 of ~2.5 μM.
-
体外实验OPM2 cell viability is effectively reduced by 3α-Aminocholestane (3AC) treatment. RPMI8226 and U266 cells show significantly less sensitivity to 3α-Aminocholestane treatment when compare with OPM2 cells, although viability is decreased significantly at concentrations of ≥12.5 μM. Treatment with 3α-Aminocholestane for 36 h severely reduces the percentage of cells in the S phase, which is accompanied by an increase of cells in the G2/M phase. In contrast, in the less proliferative RPMI8226 and U266 cells, cell cycle progression is blocked in the G0/G1 phase upon 3α-Aminocholestane treatment, in conjunction with a reduced percentage of cells undergoing the S phase.
-
体内实验It is found that 3α-Aminocholestane (3AC) results in reduced multiple myeloma (MM) growth in vivo, as determined by quantitation of free human Igλ light chain in the plasma after OPM2 challenge. In addition, reduced numbers of circulating OPM2 cells, as determined by human HLA-ABC staining, is observed in peripheral blood from 3α-Aminocholestane-treated mice compare with vehicle controls. Most importantly, 3α-Aminocholestane treatment results in significantly enhanced survival of mice after tumor challenge. In 3α-Aminocholestane-treated mice that resist treatment, it is found that MM tumors exhibit an upregulation of SHIP2, reminiscent of in vitro treatment of OPM2 cells and suggesting that SHIP1 inhibition may select for tumor cells with increased SHIP2 expression.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点Phosphatase
-
受体Phosphatase
-
研究领域——
-
适应症——
化学信息
-
CAS Number2206-20-4
-
分子量387.68
-
分子式C27H49N
-
纯度>98% (HPLC)
-
溶解度In Vitro:?Ethanol 中的溶解度 : 50 mg/mL (128.97 mM; 超声助溶)DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)
-
SMILES[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](N)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Chen Z, et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21;521(7552):357-61.
产品手册
关联产品
-
M2N12
M2N12 是细胞分裂周期 25C 蛋白磷酸酶 (Cdc25C，IC50 = 0.09 μM) 的有效且高选择性抑制剂。 M2N12 具有抗肿瘤活性。
-
Raphin1
Raphin1 是一种口服生物可利用的调节性磷酸酶 PPP1R15B (R15B) 的选择性抑制剂。
-
PTP Inhibitor IV
PTP Inhibitor IV 是一种蛋白酪氨酸磷酸酶 (PTP) 抑制剂，可竞争性抑制 DUSP14 磷酸酶活性，50 为 5.21 μM。PTP Inhibitor IV 抑制 SHP-2、PTP1B、PTP-ε、PTP Meg-2、PTP-σ、PTP-β 和 PTP-μ，50 分别为 1.8 μM、2.5 μM、8.4 μM、13 μM、20 μM、6.4 μM，和 6.7 μM。
